Keyphrases
Adhesion Defects
20%
Bone Marrow
20%
CD34+ Cells
20%
Cellular Compartments
20%
Chronic Myeloid Leukemia
100%
Developing Strategy
20%
Imatinib
20%
Induced Pluripotent Stem Cells (iPSCs)
100%
Innate Resistance
20%
Leukemia Cells
40%
Leukemia Stem Cells
60%
Long-term Survival
20%
Myeloid Leukemia Cells
100%
Normal Bone Marrow
20%
Novel Therapeutic Targets
20%
Olfactomedin 4
20%
Primitive Hematopoietic Cells
60%
Proliferation Resistance
20%
Reprogramming Technology
20%
Stem Cell Features
20%
Survival Factor
100%
Tyrosine Kinase Inhibitor
20%
Medicine and Dentistry
Cell Compartment
20%
Chronic Myelogenous Leukemia
100%
Hematopoietic Cell
60%
Imatinib
20%
Induced Pluripotent Stem Cell
100%
Leukemia
60%
Leukemia Cell
100%
Long Term Survival
20%
Somatics
20%
Survival Factor
100%
Tyrosine-Kinase Inhibitor
20%
Immunology and Microbiology
CD34
20%
Hematopoietic Cell
60%
Induced Pluripotent Stem Cell
100%
Leukemia Cell
100%
Long Term Survival
20%
Myeloid
100%
Stem Cell
60%
Survival Factor
100%
Biochemistry, Genetics and Molecular Biology
CD34
20%
Hematopoietic Cell
60%
Imatinib
20%
Induced Pluripotent Stem Cell
100%
Long Term Survival
20%
Myeloid
100%
Reprogramming
20%
Stem Cell
60%
Survival Factor
100%
Tyrosine Kinase Inhibitor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Myeloid Leukemia
100%
Imatinib
20%
Leukemia
100%
Long Term Survival
20%
Protein Tyrosine Kinase Inhibitor
20%
Survival Factor
100%